Boostimmune
Biotechnology company focused on discovering and developing first-in-class cancer therapeutics by modulating the tumor immune microenvironment. Development activities emphasize modulation of immunosuppressive myeloid cells, antibody-drug conjugates (ADCs) and immune-stimulating antibody conjugates, translational biomarker research, and progression of candidates from discovery through clinical development.
Industries
Nr. of Employees
small (1-50)
Boostimmune
Patents
Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer
US-12329814-B2
View Details
Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer
US-12329814-B2
View DetailsProducts
BIO101 (anti-TCTP antibody)
Therapeutic monoclonal antibody program targeting extracellular TCTP to inhibit accumulation/activity of immunosuppressive myeloid cells in the tumor microenvironment.
BIO103 (ADC)
Antibody-drug conjugate program targeting a novel cancer antigen for indications with high unmet medical need.
BIO104 (ADC)
Second ADC program applying differentiated target selection and conjugation strategies for oncology.
BIO105 (ISAC)
Immune-stimulating antibody conjugate program designed to activate antitumor immune responses via antibody-delivered immune stimulatory payloads.
BIO101
First-in-class immuno-oncology therapeutic targeting extracellular TCTP to reduce MDSCs in the tumor microenvironment and activate antitumor immunity.
BIO103
Topoisomerase 1 inhibitor-based antibody-drug conjugate (ADC) targeting a protein expressed during fetal development and present in cancer cells in adults.
BIO101 (anti-TCTP antibody)
Therapeutic monoclonal antibody program targeting extracellular TCTP to inhibit accumulation/activity of immunosuppressive myeloid cells in the tumor microenvironment.
BIO103 (ADC)
Antibody-drug conjugate program targeting a novel cancer antigen for indications with high unmet medical need.
BIO104 (ADC)
Second ADC program applying differentiated target selection and conjugation strategies for oncology.
BIO105 (ISAC)
Immune-stimulating antibody conjugate program designed to activate antitumor immune responses via antibody-delivered immune stimulatory payloads.
BIO101
First-in-class immuno-oncology therapeutic targeting extracellular TCTP to reduce MDSCs in the tumor microenvironment and activate antitumor immunity.
BIO103
Topoisomerase 1 inhibitor-based antibody-drug conjugate (ADC) targeting a protein expressed during fetal development and present in cancer cells in adults.
Expertise Areas
- Immuno-oncology drug discovery
- Antibody-drug conjugate (ADC) development
- Biomarker discovery and translational research
- Preclinical and early clinical development
Key Technologies
- Monoclonal antibody therapeutics
- Antibody-drug conjugates (ADC)
- Immune-stimulating antibody conjugates (ISAC)
- Blood-based biomarker assays (TCTP)
News & Updates
Announcement of Japanese patent registration for a function- and use-based antibody technology that inhibits extracellular TCTP and reduces accumulation of immunosuppressive myeloid cells (supports global commercialization of BIO101).
Selection for the Post-TIPS program to receive 15 months of commercialization funding to advance next-generation ADC and immuno-oncology programs.
Publication reporting circulating TCTP as a potential predictive biomarker associated with immunosuppressive features and clinical outcomes in metastatic gastric cancer.
Selection of the anti-TCTP antibody (candidate BIO101) and a novel-target ADC program for KDDF candidate-stage support to advance preclinical development.
Series A financing and prior Pre-A funding rounds to support research and pipeline advancement.
U.S. patent registered covering BIO101 (anti-TCTP antibody) technology.
Announcement of Japanese patent registration for a function- and use-based antibody technology that inhibits extracellular TCTP and reduces accumulation of immunosuppressive myeloid cells (supports global commercialization of BIO101).
Selection for the Post-TIPS program to receive 15 months of commercialization funding to advance next-generation ADC and immuno-oncology programs.
Publication reporting circulating TCTP as a potential predictive biomarker associated with immunosuppressive features and clinical outcomes in metastatic gastric cancer.
Selection of the anti-TCTP antibody (candidate BIO101) and a novel-target ADC program for KDDF candidate-stage support to advance preclinical development.
Series A financing and prior Pre-A funding rounds to support research and pipeline advancement.
U.S. patent registered covering BIO101 (anti-TCTP antibody) technology.